Looking at some RVX's  peers  just the CVD indication  current market caps

Medicine Co  NDCO    almost $7 Billion USD their lead drug  not even approved yet

Amarin  almost $7 billion usd   

Esperian Therapeutics  1.6 uSd  $2 billion CAD,  lead drug not approved yet

yet RVX now with science validated FDA breakthrough desigantion  , small Canadian biotech trading at tiny measly $285 Million CAD, and we have a RVX CEO talking about negotiations,  a prosperous 2020 , and what seems  like  not a worryi n the sky   about finances or promoting this latest NR , Something has to give at some point.!  The buyout valuation has to be in line oratleast  half of the   the above Market caps of their peers for CVD , and we haven't  even talked about the REnal indication valuation, cognitive indication  CHF, HIV, or the rest of their  IP

Hoping the market catches to the proper valuation of RVX peers, but than again the market always seems to know, We could be deep into final negotiations of a deal and than maybe leaks will occure like soem investment bank stating RVX is up fro sale, That will start moving the SP up quickly